Table.
Demographic and clinical characteristics of study population and factors associated with CAP-HS and MRS-HS
| Variable | Study Population (N=82)§ |
CAP-HS ΔSD (95%CI)£ |
MRS-HS ΔSD (95%CI)£ |
|---|---|---|---|
| Demographics | |||
|
| |||
| Age | 56 (51, 59) | 0.01¶ (−0.35, 0.33) | 0.22¶ (−0.12, 0.56) |
| Male | 24 (29%) | −0.13 (−0.61, 0.36) | 0.08 (−0.40, 0.57) |
| Race | |||
| African American | 49 (60%) | 0.16 (−0.34, 0.65) | 0.002 (−0.49, 0.50) |
| White | 21 (26%) | Reference | Reference |
| Other | 12 (15%) | 1.03 (0.31, 1.72) | 0.96 (0.27, 1.64) |
| Hispanic | 12 (15%) | 0.17 (−0.45, 0.80) | 0.29 (−0.34, 0.91) |
| Infection status | |||
| Uninfected | 15 (18%) | Reference | Reference |
| HIV-monoinfected | 39 (48%) | −0.26 (−0.87, 0.34) | −0.34 (−0.95, 0.27) |
| HCV-monoinfected | 7 (9%) | −0.29 (−1.20, 0.62) | −0.57 (−1.48, 0.35) |
| HIV/HCV-coinfected | 21 (26%) | −0.60 (−1.27, 0.07) | −0.41 (−1.09 0.27) |
|
| |||
| Lifestyle | |||
|
| |||
| Alcohol | |||
| None | 33 (40%) | Reference | Reference |
| Light-Moderate | 41 (50%) | −0.25 (−0.72, 0.22) | −0.03 (−0.50, 0.44) |
| Heavy | 9 (10%) | −0.42 (−1.21, 0.36) | −0.09 (−0.89, 0.70) |
| Current smoker | 40 (49%) | −0.23 (−0.67, 0.21) | −0.23 (−0.67, 0.21) |
| Current marijuana use | 35 (43%) | −0.24 (−0.68, 0.21) | −0.26 (−0.71, 0.18) |
| Injection drug use, ever | 22 (27%) | −0.25 (−0.74, 0.25) | −0.01 (−0.50, 0.49) |
|
| |||
| Metabolic | |||
|
| |||
| BMI (kg/m2) | 25 (22, 30) | 0.37* (0.21, 0.52) | 0.26* (0.10, 0.43) |
| Waist Circumference (cm) | 91 (83, 103) | 1.95¥ (1.04, 2.87) | 1.54¥ (0.58, 2.49) |
| VAT (cm3) | 163 (114, 204) | 0.71¥ (0.43, 1.00) | 0.74¥ (0.46, 1.02) |
| Abd SAT (cm3) | 254 (161, 379) | 0.46¥ (0.24, 0.69) | 0.33¥ (0.10, 0.57) |
| HOMA-IR | 1.38 (0.73, 2.58) | 0.27¥ (0.09, 0.45) | 0.28¥ (0.11, 0.46) |
|
| |||
| Liver-related | |||
|
| |||
| ALT (U/L) | 19 (14, 31) | −0.01¥ (−0.28, 0.26) | 0.11¥ (−0.16, 0.37) |
| Platelet (109/L) | 232 (194, 280) | 0.06¥ (−0.34, 0.47) | −0.16¥ (−0.57, 0.24) |
| APRI | 0.31 (0.21, 0.51) | −0.06¥ (−0.25, 0.13) | 0.08¥ (−0.11, 0.26) |
| Cirrhosis | 8 (10%) | 0.04 (−0.70, 0.79) | 0.22 (−0.52, 0.97) |
|
| |||
| HIV-related | |||
|
| |||
| Undetectable HIV RNA | 46 (78%) | 0.10 (−0.53, 0.72) | 0.16 (−0.48, 0.80) |
| Current CD4 (cells/mm3) | 658 (429, 828) | −0.01¥ (−0.31, 0.29) | −0.01¥ (−0.32, 0.29) |
| CD4 nadir (cells/mm3) | 214 (124, 327) | −0.05¥ (−0.25, 0.14) | 0.003¥ (−0.20, 0.20) |
| History of clinical AIDS | 21 (36%) | 0.40 (−0.14, 0.93) | 0.59 (0.057, 1.12) |
Bold signifies statistical significance (p<0.05);
Continuous variables are presented as median (interquartile range)
MRS and CAP values were each standardized to a mean of 0 and standard deviation (SD) of 1. Therefore, the regression coefficients and 95% confidence intervals (CI) are reported as changes in SD units of the log-transformed MRS and CAP values. Positive values refer to more steatosis and negative values refer to less steatosis. For example, with each 5 point increase in BMI, logCAP values are 0.37 SD higher and logMRS values are 0.26 SD higher.
The CAP mean (SD) was 232 dB/m (51) and the logCAP mean (SD) was 2.36 (0.10).
The MRS mean (SD) was 0.04 (0.05) and the logMRS mean (SD) was −1.68 (0.49).
CAP mean (SD) by infection status: uninfected 247 dB/m (47), HIV-infected 234 dB/m (48), HCV-monoinfected 236 dB/m (69), HIV/HCV-coinfected 218 dB/m (54)
MRS mean (SD) by infection status: uninfected 0.05 (0.05), HIV-monoinfected 0.04 (0.05), HCV-monoinfected 0.02 (0.02), HIV/HCV-coinfected 0.04 (0.05)
Per decade;
Per 5 point increase;
Per doubling